Clicky

Cynata Therapeutics Ltd Ordinar(CYYNF)

Description: Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.


Keywords: Biotechnology Life Sciences Biology Surgery Partnership Cell Therapy Asthma Cell Biology Neurosurgery College Acute Respiratory Distress Syndrome Coronary Artery Disease Fuji Mesenchymal Stem Cell Heart Attack Artery Brain Cancer Host Disease Graft Versus Host Disease A Therapeutic Artery Disease Mesoblast Stem Cell Therapies Fujifilm Respiratory Distress Syndrome Harvard Cymer Monash University Treatment Of Graft Versus Host Disease University Of Sydney Cyp 001 Mesenchymal Stem Cell Technology Cymerus Technology University Of New South Wales

Home Page: www.cynata.com

100 Cubitt Street
Cremorne, VIC 3121
Australia
Phone: 61 3 7067 6940


Officers

Name Title
Dr. Kilian Kelly MD, CEO & Director
Dr. Jolanta Airey Chief Medical Officer
Dr. Mathias Kroll Chief Business Officer
Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D. Company Secretary

Exchange: PINK

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 7.1312
Price-to-Sales TTM: 14.8348
IPO Date:
Fiscal Year End: June
Full Time Employees: 0
Back to stocks